Equity Details
Price & Market Data
Price: $2.96
Daily Change: +$0.38 / 12.83%
Daily Range: $2.60 - $4.47
Market Cap: $19,461,562
Daily Volume: 20,210,257
Performance Metrics
1 Week: 174.8%
1 Month: 682.1%
3 Months: 388.2%
6 Months: 53.10%
1 Year: -64.94%
YTD: 205.0%
About HCW Biologics Inc. (HCWB)
Dive into the latest financial snapshot of HCW Biologics Inc. (HCWB). With a current trading price of 2.96, the stock has experienced a daily shift of +$0.38 / 12.83%. The company's market capitalization stands impressively at 19,461,562. Track its year-to-date performance, which is at 205.0%, alongside its weekly, monthly, and yearly trends.
Company Details
Employees: 35
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
